Immucell Corp (ICCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,157 | -2,671 | -1,970 | -438 | -5,775 |
| Depreciation Amortization | 2,730 | 2,045 | 1,359 | 678 | 2,740 |
| Accounts receivable | -1,586 | -123 | 235 | -437 | -427 |
| Accounts payable and accrued liabilities | 363 | 387 | 450 | 20 | 157 |
| Other Working Capital | -407 | 828 | 1,492 | 135 | -2,112 |
| Other Operating Activity | 1,414 | -106 | -566 | 461 | 743 |
| Operating Cash Flow | $358 | $361 | $1,000 | $419 | $-4,674 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -461 | -265 | -177 | -70 | -1,890 |
| Investing Cash Flow | $-461 | $-265 | $-177 | $-70 | $-1,890 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 5,000 |
| Common Stock Issued | 4,648 | 4,109 | 418 | N/A | 19 |
| Other Financing Activity | -1,765 | -1,375 | -896 | -367 | -3,267 |
| Financing Cash Flow | $2,883 | $2,734 | $-478 | $-367 | $1,752 |
| Beginning Cash Position | 979 | 979 | 979 | 979 | 5,792 |
| End Cash Position | 3,758 | 3,809 | 1,324 | 960 | 979 |
| Net Cash Flow | $2,780 | $2,830 | $346 | $-18 | $-4,813 |
| Free Cash Flow | |||||
| Operating Cash Flow | 358 | 361 | 1,000 | 419 | -4,674 |
| Capital Expenditure | -466 | -270 | -181 | -70 | -1,893 |
| Free Cash Flow | -108 | 92 | 819 | 348 | -6,567 |